home  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     zynerba pharmaceuticals a clinicalstage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs learn more our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy osteoarthritis fragile x syndrome fibromyalgia and peripheral neuropathic pain through synthetic cannabinoid therapeutics formulated for transdermal delivery our team our team has a proven track record of success in developing novel transdermal products for patients in need more  our development pipeline we are developing two proprietary products a transdermal synthetic cbd gel for refractory epilepsy osteoarthritis and fragile x syndrome and a novel synthetic thc prodrug transdermal patch for two pain indications – fibromyalgia and peripheral neuropathic pain more  for investors learn more about our company and our potential more  latest news  zynerba pharmaceuticals mourns passing of director cynthia a rask learn more  zynerba pharmaceuticals added to the russell ® index learn more product candidates  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     our development pipeline includes two lead product candidates zyn and zyn which are being evaluated in five therapeutic indications our development pipeline currently includes two programs studying synthetic cannabinoid therapeutics across multiple therapeutic areas zyn – cbd gel zyn is the first and only synthetic cbd a nonpsychoactive cannabinoid formulated as a patentprotected permeationenhanced gel for transdermal delivery through the skin and into the circulatory system zyn is in phase  clinical development in patients with refractory epilepsy in patients with osteoarthritis of the knee as well as in patients with fragile x syndrome in february  the fda granted orphandrug designation of zyn for the treatment of patients with fragile x syndrome in the us zyn – thc prodrug patch zyn is a prodrug of thc that enables transdermal delivery through the skin and into the circulatory system via a patch a phase  clinical program for zyn was initiated in the first half of  development status and upcoming milestones these timelines are subject to change due to regulatory clinical and other considerations  upcoming milestones product study  key milestone timing zyn  epilepsy in adults with focal seizures – star   phase  results  julyaugust  zyn osteoarthritis – stop phase  results julyaugust  zyn  fragile x syndrome – fabc phase  results september  zyn safety and pk phase  initiation h  zyn fibromyalgia phase  initiation h  zyn  peripheral neuropathic pain phase  initiation h  cannabinoids cannabinoids are a class of compounds derived from cannabis plants the two primary cannabinoids contain in cannabis are cannabidiol cbd and δtetrahydrocannabinol thc cannabinoid  cannabidiol  δtetrahydrocannabinol  activity nonpsychoactive multiple mechanisms psychoactive antinociceptive agonist of cb and cb receptors indications being developed epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain potential future indications posttraumatic stress disorder autoimmune diseases chronic cancer pain chronic pain gi disorders zynerba asset cbd gel – zyn thc prodrug patch – zyn patent protection   thc and cbd safety clinical data suggest that thc and cbd have a high therapeutic index with low toxicity in the nabiximols clinical program dizziness and fatigue were considered very common   adverse events these occurred in the first four weeks of exposure were mild to moderate and resolved within a few days with continued treatment  nabiximols are not recommended for use in children or adolescents below  years of age due to lack of safety and efficacy data in nonclinical studies effects were observed at exposures considered in excess of human exposure suggesting little relevance to clinical use   references  fine pg rosenfeld mj the endocannabinoid system cannabinoids and pain rambam maimodies med j  e  sativex summary of product characteristics uk  prodrugs zyn is a prodrug learn more about prodrugs read more publications find journal publications related to cannabinoids view now zyne stock quote  zynerba pharmaceuticals inc common stock price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  zyne zynerba pharmaceuticals inc common stock quote  summary data zyne        get zyne alerts delayed  data as of jul      find a broker to begin trading zyne now exchangenasdaq industry health care community rating zyne     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks new secfilings news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock na  na  year target  todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple ne forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year ne earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec unless the context indicates otherwise the terms zynerba zynerba pharmaceuticals we us our our company and our business refer to zynerba pharmaceuticals inc company overview we are a clinical stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments for patients with high unmet needs we are evaluating two patent protected product candidates zyn and zyn in five indications we are studying zyn in adult patients with refractory epileptic focal seizures formerly known as complex partial seizures and osteoarthritis or oa and in pediatric patients with fragile x syndrome or fxs we intend to study zyn in patients with fibromyalgia and peripheral neuropathic pain   more    risk grade where does zyne fit in the risk graph news for zyne gainers  losers of july  flks myok syrs pcrx reta   pm  rtt news zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month   pm  seeking alpha is the fda biotechs best friend   am  seeking alpha these  marijuana stocks all jumped at least  last week   am  motley fool top marijuana stocks on the nasdaq   am  investopedia  subscribe more zyne news  commentary read zyne press releases consensus recommendation analyst info annual eps est  quarterly eps est  peg ratio  mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex fibromyalgia  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     fibromyalgia is a chronic health problem that causes pain throughout the body and other symptoms such as fatigue and cognitive memory or thought problems to learn more national fibromyalgia foundation national fibromyalgia  chronic pain association national fibromyalgia partnership the american fibromyalgia syndrome association fibromyalgia network national institute of arthritis and musculoskeletal and skin diseases zyn – thc prodrug patch intended to treat fibromyalgia and peripheral neuropathic pain learn more osteoarthritis  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     osteoarthritis is a degenerative joint disease that leads to wear and tear of the joints and affects the cartilage joint lining ligaments and bone it is the most common form of joint disease and tends to occur most often in the hand joints spine hip knees and great toes it is characterized by the breakdown of the joint cartilage bony changes in the joints and deterioration of the tendons and ligaments leading to pain and inflammation of the joint lining to learn more arthritis foundation american college of rheumatology national institute of arthritis and musculoskeletal and skin diseases american pain foundation   zyn – cbd gel intended to treat refractory epilepsy osteoarthritis and fragile x syndrome learn more product candidates  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     our development pipeline includes two lead product candidates zyn and zyn which are being evaluated in five therapeutic indications our development pipeline currently includes two programs studying synthetic cannabinoid therapeutics across multiple therapeutic areas zyn – cbd gel zyn is the first and only synthetic cbd a nonpsychoactive cannabinoid formulated as a patentprotected permeationenhanced gel for transdermal delivery through the skin and into the circulatory system zyn is in phase  clinical development in patients with refractory epilepsy in patients with osteoarthritis of the knee as well as in patients with fragile x syndrome in february  the fda granted orphandrug designation of zyn for the treatment of patients with fragile x syndrome in the us zyn – thc prodrug patch zyn is a prodrug of thc that enables transdermal delivery through the skin and into the circulatory system via a patch a phase  clinical program for zyn was initiated in the first half of  development status and upcoming milestones these timelines are subject to change due to regulatory clinical and other considerations  upcoming milestones product study  key milestone timing zyn  epilepsy in adults with focal seizures – star   phase  results  julyaugust  zyn osteoarthritis – stop phase  results julyaugust  zyn  fragile x syndrome – fabc phase  results september  zyn safety and pk phase  initiation h  zyn fibromyalgia phase  initiation h  zyn  peripheral neuropathic pain phase  initiation h  cannabinoids cannabinoids are a class of compounds derived from cannabis plants the two primary cannabinoids contain in cannabis are cannabidiol cbd and δtetrahydrocannabinol thc cannabinoid  cannabidiol  δtetrahydrocannabinol  activity nonpsychoactive multiple mechanisms psychoactive antinociceptive agonist of cb and cb receptors indications being developed epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain potential future indications posttraumatic stress disorder autoimmune diseases chronic cancer pain chronic pain gi disorders zynerba asset cbd gel – zyn thc prodrug patch – zyn patent protection   thc and cbd safety clinical data suggest that thc and cbd have a high therapeutic index with low toxicity in the nabiximols clinical program dizziness and fatigue were considered very common   adverse events these occurred in the first four weeks of exposure were mild to moderate and resolved within a few days with continued treatment  nabiximols are not recommended for use in children or adolescents below  years of age due to lack of safety and efficacy data in nonclinical studies effects were observed at exposures considered in excess of human exposure suggesting little relevance to clinical use   references  fine pg rosenfeld mj the endocannabinoid system cannabinoids and pain rambam maimodies med j  e  sativex summary of product characteristics uk  prodrugs zyn is a prodrug learn more about prodrugs read more publications find journal publications related to cannabinoids view now patient resources  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     we believe that knowledge is power the more you know about your medical condition symptoms and the physiological causes the more likely you and your healthcare provider can find a treatment option that works for you we believe you may find the following resources valuable we encourage you to talk with your healthcare practitioner about your symptoms and what treatment options might best address your individual symptoms access our patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  management  zynerba  zynerba about us about us management board of directors scientific advisory board contact us product candidates development pipeline zyn – cbd gel zyn – thc prodrug patch publications manuscripts and presentations patient resources epilepsy osteoarthritis fragile x syndrome fibromyalgia peripheral neuropathic pain investor relations stock quote news events  webcasts financial information analyst coverage corporate governance investor faqs irs form  investor contacts news toggle navigation     management armando anido chairman of the board and chief executive officer armando anido has served as our chairman and chief executive officerceo since october  mr anido has more than  years of executive operational and commercial leadership experience in the biopharmaceutical industry particularly in leading cns transdermal patch and gel products through the entire product life cycle prior to zynerba mr anido served as ceo of two publicly trade companies most recently he was the ceo of nupathe nasdaq path which was acquired by teva pharmaceuticals in february  at nupathe he led the company through fda approval of its lead product zecuity® the first transdermal patch for migraine to prelaunch before successfully selling the company to teva he also served as president and ceo of auxilium pharmaceuticals nasdaq auxl where under his leadership sales grew from  million in  to more than  million in  and market capitalization increased from  million to more than  million prior to auxilium mr anido served as executive vice president sales and marketing at medimmune and prior to that in senior sales and marketing positions at glaxowellcome and lederle laboratories at glaxowellcome he was vice president central nervous system marketing responsible for the commercialization of the epilepsy migraine and depression businesses in the us he is currently a member of the board of directors of pabio and he was a member of the board of directors of adolor until it was sold to cubist in december  mr anido earned a bs in pharmacy and an mba from west virginia university   terri b sebree president terri b sebree has served as our president since october  ms sebree has more than  years of executive development and operational experience in the biopharmaceutical industry particularly in cns product development including epilepsy pain depression and schizophrenia she has completed more than  regulatory submissions and approvals of new pharmaceutical products including transdermal patch and gel products prior to zynerba ms sebree cofounded and served as president of nupathe nasdaq path which was acquired by teva pharmaceuticals in february  at nupathe she successfully led the effort to develop achieve regulatory approval and complete manufacturing of the company’s lead product zecuity the first transdermal patch for migraine before founding nupathe in  ms sebree served as senior vice president development of auxilium pharmaceuticals nasdaq auxl where she led the testim® gel development and approval program previously ms sebree served as executive vice president us operations at omnicare nyse ocr prior to that ms sebree served in a variety of management roles with abbott laboratories for more than nine years ms sebree holds a bs from texas am university   jim fickenscher chief financial officer vice president corporate development jim fickenscher serves as zynerba’s chief financial officer vice president corporate development mr fickenscher is a seasoned executive who has held management financial and strategic planning roles in his year tenure in the pharmaceutical industry prior to zynerba he was senior vice president chief financial officer at antares pharma nasdaq atrs a commercial pharmaceutical company focused on selfadministered parenteral products he has also held the role of chief financial officer at both auxilium pharmaceuticals nasdaq auxl and aventis behring as well as additional general management business development and strategic planning responsibilities mr fickenscher holds a bs from bloomsburg university of pennsylvania he is also a member of the american institute of certified public accountants   suzanne m hanlon general counsel and vice president human resources suzanne m hanlon has served as our general counsel and vice president of human resources since october  ms hanlon is an accomplished attorney with  years of legal experience particularly in public life sciences companies she offers expertise in contracts licensing compliance clinical trials regulatory litigation intellectual property and employment law prior to joining zynerba she served as vice president associate general counsel of nupathe nasdaq path which was acquired by teva pharmaceuticals in february  at nupathe she successfully led the intellectual property strategy and the contracts effort in addition to managing the human resources function and she partnered with senior management to complete a successful ipo previously she was chief development counsel at auxilium pharmaceuticals nasdaq auxl and vice president of global contracts at omnicare clinical research nyse ocr ms hanlon received her jd degree from villanova university school of law   donna l gutterman pharmd vice president medical donna gutterman pharmd has served as our vice president medical since october  dr gutterman is a senior pharmaceutical executive with more than  years of experience in clinical development medical affairs and commercialization in cns therapy areas during her career she has led numerous successful clinical development programs regulatory approvals and product launches prior to joining zynerba she served as head of medical affairs for nupathe nasdaq path through approval and prelaunch of its lead product zecuity the first transdermal patch for migraine prior to the company being acquired by teva pharmaceuticals in  previously dr gutterman served in a variety of executive roles at glaxosmithkline for more than  years there she was instrumental in the clinical development of imitrex® and led the medical affairs teams in neurology and psychiatry additionally she led  several successful commercial product launches she earned her doctor of pharmacy degree at the university of kentucky college of pharmacy and her mba at the university of north carolina unc kenanflagler business school dr gutterman also serves on the board of visitors at unc eshelman school of pharmacy and as a board member of several nonprofit organizations   ray mannion vice president manufacturing ray mannion has served as our vice president of manufacturing since april  mr mannion has more than  years of international manufacturing operations and engineering experience in the pharmaceutical medical devices and electrical connection systems industries prior to zynerba he was senior director third party operations for teva pharmaceuticals inc nyse teva where he successfully managed the production scale up for the commercial launch of the zecuity® migraine patch while also managing all technical aspects of the project in addition to his activities with zecuity he led a supplier relations team where he collaborated with teva stakeholders in managing a portfolio of key strategic suppliers in the areas of contract negotiations product supply new product launches and product serialization prior to teva mr mannion held the position of vice president of commercial manufacturing at nupathe nasdaq path where he led the production scale up and process validation efforts for the zecuity migraine patch prior to nupathe mr mannion served as the vice president of operations for puricore inc where he managed internal and external manufacturing engineering quality assurance  regulatory affairs supply chain customer service and field service for puricore’s us and uk operations in addition mr mannion has held various operations engineering and manufacturing roles with animas corporation kensey nash corporation and amp incorporated mr mannion received a bs in industrial engineering from rutgers university new brunswick nj and an mba from shippensburg university shippensburg pa   carol o’neill vice president development carol o’neill has served as our vice president development since october  she has more than  years of development and operational experience in the biopharmaceutical industry ms o’neill has completed regulatory submissions and achieved approvals of new pharmaceutical products including a transdermal patch and a transdermal gel prior to joining zynerba she served as vice president development operations of nupathe nasdaq path which was acquired by teva pharmaceuticals in february  at nupathe she successfully managed the research and development aspects of the clinical and nonclinical programs of the company’s lead product zecuity the first transdermal patch for migraine previously she was senior director clinical operations at auxilium pharmaceuticals nasdaq auxl and senior director of operations analysis at omnicare clinical research nyse ocr ms o’neill holds a business administration degree from lakehead university ontario canada   will roberts vice president investor relations and corporate communications will roberts serves as our vice president investor relations and corporate communications mr roberts is a successful communications officer with  years of biotechnologypharmaceutical experience in corporate communications investor and public relations and preclinical research prior to zynerba he served as vice president investor relations and corporate communications for adaptimmune therapeutics plc nasdaq adap where he supported the company’s may  ipo and developed the company’s communications strategies he spent  years with viropharma inc nasdaq vphm a biotechnology company routinely recognized for excellence in investor relations and communications culminating in his tenure as vice president corporate communications there he was responsible for leading global investor and corporate communications patient advocacy disease awareness programming and global communications support for the company’s marketed products mr roberts began his professional career at medimmune inc nasdaq medi in  he spent  years with the company transitioning from his initial role as a molecular microbiology research scientist into investor relations in  mr roberts received a ba in biology from the university of virginia and an mba from the keller graduate school of management   brian rosenberger vice president commercial brian rosenberger serves as zynerba’s vice president commercial over his year career in the pharmaceutical industry mr rosenberger has held several leadership roles in marketing sales business development analytics and alliance management prior to zynerba he was vice president alliance  strategic portfolio management of cipher pharmaceuticals a publiclytraded canadianbased dermatology company where he managed the company’s global portfolio mr rosenberger also held various roles of increasing responsibility at auxilium a specialty biopharmaceutical company in his last role as executive director corporate development  licensing and alliance management he participated in several transformational ma licensing and copromotion deals through and including endo international’s acquisition of auxilium pharmaceuticals nasdaq auxl in january  mr rosenberger held sales managerial positions at neurocrine biosciences during the initial commercial buildout of the organization and spent over a decade at glaxosmithkline in various us and global commercial roles within specialty markets including neurohealth epilepsy marketing mr rosenberger received a ba double major in political sciencepolicy and management studies from dickinson college in carlisle pa   nancy tich phd vice president clinical nancy tich phd serves as zynerba’s vice president clinical she has more than  years of clinical project management in the biopharmaceutical industry prior to joining zynerba she served as senior director project management oncology at covance nyse cvd which was acquired by labcorp in november  at covance she successfully managed numerous oncology clinical projects across various stages of development previously she was vice president client project management at omnicare nyse ocr and senior client project manager at abbott labs nyseabt dr tich earned a doctorate in cell physiology from university of minnesota and a bachelor of arts from northwestern university   marcel o bonnmiller phd director cannabinoid research marcel o bonnmiller phd serves as director of cannabinoid research dr bonnmiller is also an adjunct assistant professor in the department of psychiatry at the university of pennsylvania perelman school of medicine prior to joining zynerba he was a research health science specialist at the center of excellence in substance abuse treatment and education at the philadelphia veterans affairs medical center in philadelphia pa as well as at the national center for posttraumatic stress disorder ptsd dissemination and training division and center for innovation to implementation at the veterans affairs palo alto health care system in menlo park ca he is also the former executive director at the institute for research on cannabinoids iroc in colorado springs co as an early research pioneer of cannabis comorbidity dr bonnmiller has spent over a decade investigating the interrelations between cannabis and a number of health conditions including chronic pain hiv ptsd and sleep disorders for the purposes of treatment development and refinement his research has spanned laboratorycontrolled to clinical trials and preimplementation dr bonnmiller has published well over  peerreviewed empirical publications and he serves on the editorial boards of six scientific journals dr bonnmiller earned a ba in psychology and phd in clinical psychology from the university of vermont he completed a predoctoral clinical psychology internship at the veterans affairs palo alto health care system and a joint postdoctoral fellowship at the veterans affairs palo alto health care system  stanford university school of medicine   publications find journal publications related to cannabinoids view now email alerts stay up to date on the latest zynerba news learn more zyne stock price  zynerba pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern a breaking elon musk details tesla model  pricing range a tesla standard model  will cost  longrange model will cost   updated wall street isn’t ready for a point tumble in the dow industrials  barrons buzz robo  facebook and twitter trading on news  a wild week in washington  updated the dark side of cruises  trump to police dont be too nice  updated the highest paid athletes in the world in one chart  updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family  updated here are  coworkers you should avoid like the plague — especially in meetings to be replaced home investing quotes stocks united states zyne overview compare quotes stock screener earnings calendar sectors nasdaq zyne us nasdaq join td ameritrade find a broker zynerba pharmaceuticals inc watchlist createzynealert after hours last updated jul    pm edt delayed quote     after hours volume  close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones opinion how investors can separate the winners from the losers in the marijuana industry apr   at  am et by michael kahn opinion harry boxer these four momentum stocks are breaking out feb   at  pm et by harry boxer clinical development news jan  jan   at  pm et on the wall street journal it’s time for investors to relearn the lost art of reading apr   at  pm et on the wall street journal recent news other news press releases zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month jul   at  pm et on seeking alpha is the fda biotechs best friend is the fda biotechs best friend jul   at  am et on seeking alpha these  marijuana stocks all jumped at least  last week jul   at  am et on motley fool top marijuana stocks on the nasdaq most marijuana companies trade otc but these names are listed on the nasdaq and enjoy greater liquidity jul   at  am et on investopediacom forget gw pharmaceuticals these  stocks are better buys jul   at  am et on motley fool  things you need to know about marijuana stock zynerba pharmaceuticals jul   at  am et on motley fool gw pullback is a buy gw pullback is a buy jul   at  am et on seeking alpha brunch craft beer and investing a millennials portfolio brunch craft beer and investing a millennials portfolio jul   at  pm et on seeking alpha wow  of patients prefer medical marijuana to opioids new survey shows jul   at  am et on motley fool the  best stocks for  contest hits ’s midpoint the  best stocks for  contest hits ’s midpoint jul   at  pm et on investorplacecom zynerba shows promise in burgeoning cannabinoid market zynerba shows promise in burgeoning cannabinoid market jul   at  pm et on seeking alpha political risk increases for medical marijuana political risk increases for medical marijuana jul   at  am et on seeking alpha  marijuana stocks looking to combat the opioid epidemic jul   at  am et on motley fool zynerba pharmaceuticals zyne investor presentation  slideshow zynerba pharmaceuticals zyne investor presentation  slideshow jun   at  am et on seeking alpha zynerba pharmaceuticals scalable with less risk  debra borchardts idea of the month zynerba pharmaceuticals scalable with less risk  debra borchardts idea of the month jun   at  am et on seeking alpha  marijuana stocks it is still too early to buy the sector  marijuana stocks it is still too early to buy the sector jun   at  am et on seeking alpha medical marijuana investing recommendations medical marijuana investing recommendations jun   at  pm et on seeking alpha maxim bullish on zynerba pharmaceuticals inc zyne following meeting with management many investors hope to win big on biotech stocks as shares can sky rocket when  jun   at  pm et on smarteranalyst biotech forum daily digest  spotlight on  oncology concern verastem biotech forum daily digest  spotlight on  oncology concern verastem jun   at  am et on seeking alpha marijuana stock investors in awe as california goes toetotoe with the trump administration jun   at  am et on motley fool zynerba pharmaceuticals mourns passing of director cynthia a rask zynerba pharmaceuticals mourns passing of director cynthia a rask jul   at  am et on globenewswire biotech players lead the growth charge in the legal cannabis market biotech players lead the growth charge in the legal cannabis market jul   at  am et on pr newswire  prf potential blockbuster treatment for alzheimers disease stands out among medical cannabis companies potential blockbuster treatment for alzheimers disease stands out among medical cannabis companies jul   at  am et on pr newswire  prf billionaires bet big on canadas newest  billion market billionaires bet big on canadas newest  billion market jul   at  pm et on pr newswire  prf sales of legal cannabis products are expected to accelerate sales of legal cannabis products are expected to accelerate jul   at  am et on pr newswire  prf todays research reports on trending tickers insys therapeutics and zynerba pharmaceuticals todays research reports on trending tickers insys therapeutics and zynerba pharmaceuticals jul   at  am et on accesswire legal cannabis and cbdbased products projected to gain popularity legal cannabis and cbdbased products projected to gain popularity jun   at  am et on pr newswire  prf zynerba pharmaceuticals added to the russell r index zynerba pharmaceuticals added to the russell r index jun   at  am et on globenewswire zynerba pharmaceuticals initiates zyn phase  clinical program zynerba pharmaceuticals initiates zyn phase  clinical program jun   at  am et on globenewswire consumers spending on legal cannabis products projected to grow consumers spending on legal cannabis products projected to grow jun   at  am et on pr newswire  prf zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome jun   at  am et on globenewswire legal cannabis and cbd markets are projected to grow legal cannabis and cbd markets are projected to grow jun   at  am et on pr newswire  prf zynerba pharmaceuticals to present at the jefferies  global healthcare conference zynerba pharmaceuticals to present at the jefferies  global healthcare conference jun   at  am et on globenewswire how these generic drugs stocks are faring  myos rens technology akari therapeutics flexion therapeutics and zynerba pharma how these generic drugs stocks are faring  myos rens technology akari therapeutics flexion therapeutics and zynerba pharma may   at  am et on pr newswire  prf cannabisbased therapies with potential to dull the pain of opioid abuse cannabisbased therapies with potential to dull the pain of opioid abuse may   at  am et on pr newswire  prf legal cannabis and cbd markets grow in the united states legal cannabis and cbd markets grow in the united states may   at  am et on pr newswire  prf zynerba pharmaceuticals reports first quarter  financial results and operational highlights zynerba pharmaceuticals reports first quarter  financial results and operational highlights may   at  am et on globenewswire the creation of jobs in the legal cannabis market the creation of jobs in the legal cannabis market may   at  am et on pr newswire  prf the legal cannabis market expected to witness wider adoption apr   at  am et on pr newswire  prf how these generic drugs stocks are faring  zynerba pharma patheon scynexis and flexion therapeutics apr   at  am et on pr newswire  prf zynerba pharmaceuticals inc zynerba pharmaceuticals inc engages in the research and development of drugs its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery the company was founded by audra l stinchcomb on january   and is headquartered in devon pa see full profile analyst ratings sell under hold over buy number of ratings  full ratings viridian discusses the spicer effect on marijuana stocks it wasnt the deathblow some people were afraid of jun   at  am et on benzingacom catalysts growing like weeds for zynerba next quarter may   at  pm et on benzingacom  biggest price target changes for tuesday mar   at  am et on benzingacom competitors name chg  market cap omeros corp  m ohr pharmaceutical inc  m oncomed pharmaceuticals inc  m omni bio pharmaceutical inc  m competitor data provided by partner content trending tickers powered by dvax  sq  wfc  ben  wy  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience zyne key statistics  zynerba pharmaceuticals inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close zynerba pharmaceuticals inc nasdaq zyne go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus zynerba pharmaceuticals inc after hours  quotes are delayed by  min jul    pm zyne quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description zynerba pharmaceuticals inc engages in the research and development of drugs its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery the company was founded by audra l stinchcomb on january   and is headquartered in devon pa valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr armando anido   chairman  chief executive officer ms terri b sebree   president mr james e fickenscher   chief financial officer  vpcorporate development dr nancy tich   vice presidentclinical operations dr donna l gutterman   vice presidentmedical insider actions – purchase – sale  – number of transactions  date name shares transaction value  armando anido chairman  chief exec officer director    acquisition at  per share   armando anido chairman  chief exec officer director    acquisition at  per share   james e fickenscher chief financial officer    acquisition at  per share   michael rapoport    acquisition at  per share   james e fickenscher chief financial officer    acquisition at  per share   james e fickenscher chief financial officer    acquisition at  per share   suzanne m hanlon sec general counsel  vp hr    disposition at  per share   michael rapoport      richard a baron chief financial officer    derivativenonderivative trans at  per share   michael rapoport    derivativenonderivative trans at  per share   armando anido chairman  chief exec officer director    derivativenonderivative trans at  per share   armando anido chairman  chief exec officer director    derivativenonderivative trans at  per share   thomas l harrison director    acquisition at  per share  newslatestcompanyuszyne marketwatch news on zyne how investors can separate the winners from the losers in the marijuana industry  am april    michael kahn harry boxer these four momentum stocks are breaking out  pm feb    harry boxer newsnonmarketwatchcompanyuszyne other news on zyne zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month  pm july    seeking alpha is the fda biotechs best friend  am july    seeking alpha these  marijuana stocks all jumped at least  last week  am july    motley fool top marijuana stocks on the nasdaq  am july    investopediacom forget gw pharmaceuticals these  stocks are better buys  am july    motley fool  things you need to know about marijuana stock zynerba pharmaceuticals  am july    motley fool gw pullback is a buy  am july    seeking alpha brunch craft beer and investing a millennials portfolio  pm july    seeking alpha wow  of patients prefer medical marijuana to opioids new survey shows  am july    motley fool the  best stocks for  contest hits ’s midpoint  pm july    investorplacecom zynerba shows promise in burgeoning cannabinoid market  pm july    seeking alpha political risk increases for medical marijuana  am july    seeking alpha  marijuana stocks looking to combat the opioid epidemic  am july    motley fool zynerba pharmaceuticals zyne investor presentation  slideshow  am june    seeking alpha zynerba pharmaceuticals scalable with less risk  debra borchardts idea of the month  am june    seeking alpha  marijuana stocks it is still too early to buy the sector  am june    seeking alpha medical marijuana investing recommendations  pm june    seeking alpha maxim bullish on zynerba pharmaceuticals inc zyne following meeting with management  pm june    smarteranalyst biotech forum daily digest  spotlight on  oncology concern verastem  am june    seeking alpha marijuana stock investors in awe as california goes toetotoe with the trump administration  am june    motley fool loading more headlines at a glance zynerba pharmaceuticals inc  west lancaster avenue suite  devon pennsylvania  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue  net income m employees  annual report for zyne newspressreleasecompanyuszyne press releases on zyne zynerba pharmaceuticals mourns passing of director cynthia a rask  am july    globenewswire biotech players lead the growth charge in the legal cannabis market  am july    pr newswire  prf potential blockbuster treatment for alzheimers disease stands out among medical cannabis companies  am july    pr newswire  prf billionaires bet big on canadas newest  billion market  pm july    pr newswire  prf sales of legal cannabis products are expected to accelerate  am july    pr newswire  prf todays research reports on trending tickers insys therapeutics and zynerba pharmaceuticals  am july    accesswire hydrofarm inc partners with serruya private equity  am july    businesswire  bzx legal cannabis and cbdbased products projected to gain popularity  am june    pr newswire  prf zynerba pharmaceuticals added to the russell r index  am june    globenewswire zynerba pharmaceuticals initiates zyn phase  clinical program  am june    globenewswire consumers spending on legal cannabis products projected to grow  am june    pr newswire  prf zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome  am june    globenewswire legal cannabis and cbd markets are projected to grow  am june    pr newswire  prf zynerba pharmaceuticals to present at the jefferies  global healthcare conference  am june    globenewswire how these generic drugs stocks are faring  myos rens technology akari therapeutics flexion therapeutics and zynerba pharma  am may    pr newswire  prf cannabisbased therapies with potential to dull the pain of opioid abuse  am may    pr newswire  prf legal cannabis and cbd markets grow in the united states  am may    pr newswire  prf zynerba pharmaceuticals reports first quarter  financial results and operational highlights  am may    globenewswire the creation of jobs in the legal cannabis market  am may    pr newswire  prf the legal cannabis market expected to witness wider adoption  am april    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome nasdaqzyne english français register sign in zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome  topline data from this study remains on track to report in september   june    et  source zynerba pharmaceuticals inc devon pa june   globe newswire  zynerba pharmaceuticals inc nasdaqzyne a clinicalstage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments today announced that it has met its enrollment target of  patients in its phase  fabc treatment of fragile x syndrome anxiety and behavioral challenges with cbd clinical trial evaluating zyn cannabidiol cbd gel in children with fragile x syndrome fxs zyn cbd gel is the first and only patentprotected synthetic cbd that is formulated as a permeationenhanced gel for transdermal delivery and was awarded orphan drug designation by the us food and drug administration for the treatment for fxs patients between the ages of  and  years with fragile x syndrome have been enrolled in the exploratory fabc trial which is designed to evaluate the safety and efficacy of zyn cbd gel administered over a week period in fxs the study is evaluating  mg of cbd in zyn  gel once daily which may be titrated up to  mg two times per day during the sixweek titration period between weeks six and twelve patients will receive a maintenance dose of  mg  mg or  mg daily of cbd in zyn  gel the primary outcome measures include changes in anxiety depression and mood as measured by the adams scale a patient reported outcomes questionnaire that has been validated in fxs other measurements that are being observed include the aberrant behavior checklist and visual analog scale vas to assess for hyperactivityimpulsivity “this achievement marks a key milestone for us and for families facing the challenges of fragile x syndrome” said armando anido chairman and chief executive officer of zynerba “fragile x is a devastating genetic disorder for patients and their caregivers we believe that synthetic cbd holds great therapeutic promise in this setting as it may compensate for the dysregulation of the endocannabinoid pathway and in doing so may treat many of the associated neurological symptoms we look forward to reporting data from this trial in september of this year” fragile x syndrome is an autism spectrum disorder and the most common inherited intellectual disability in males and a significant cause of intellectual disability in females it is caused by a mutation in the fragile x mental retardation gene located on the x chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids ag and anandamide the disorder negatively affects synaptic function plasticity and neuronal connections and results in a spectrum of intellectual disabilities social anxiety and memory problems in the us there are about  patients suffering with fxs about zyn cbd gel zynerba’s zyn cbd gel is the first and only synthetic cbd formulated as a patentprotected permeationenhanced gel and is being studied in adult epilepsy patients with focal seizures in osteoarthritis and in children with fxs zyn is a clear permeationenhanced gel that is designed to provide consistent controlled drug delivery transdermally with once or twicedaily dosing transdermal therapeutics are absorbed through the skin directly into the systemic circulation avoiding firstpass liver metabolism and potentially enabling lower dosage levels of active pharmaceutical ingredients and rapid and reliable absorption with high bioavailability in addition transdermal delivery avoids the gastrointestinal tract and potential stomach acid degradation of cbd into thc associated with psychoactive effects as demonstrated in a zynerbasponsored in vitro study about zynerba pharmaceuticals inczynerba pharmaceuticals nasdaqzyne is a clinicalstage specialty pharmaceutical company focused on developing and commercializing proprietary nextgeneration synthetic cannabinoid therapeutics formulated for transdermal delivery zynerba is developing therapeutic candidates based on proprietary transdermal technologies that if successfully developed may allow sustained consistent and controlled delivery of therapeutic levels of two cannabinoids cannabidiol cbd a nonpsychoactive cannabinoid and tetrahydrocannabinol thc transdermal delivery has the potential to reduce adverse effects associated with oral dosing zyn the company’s cbd gel is the first and only synthetic cbd formulated as a patentprotected permeationenhanced gel in march  the company completed enrollment in the phase  star  synthetic transdermal cannabidiol for the treatment of epilepsy clinical trial of zyn cbd gel in refractory epilepsy patients with focal seizures the most common form of epilepsy in adults also in march  the phase  stop synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis clinical trial in patients with knee pain due to osteoarthritis was fully enrolled in june  the company completed target enrollment in its exploratory phase  fabc treatment of fragile x syndrome anxiety and behavioral challenges with cbd clinical trial in children with fragile x syndrome zynerba is also developing zyn which utilizes a synthetically manufactured prodrug of thc a phase  clinical study for zyn is planned to begin by the end of the first half of  learn more at wwwzynerbacom and follow the company on twitter at zynerbapharma cautionary note on forwardlooking statementsthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  we may in some cases use terms such as “predicts” “believes” “potential” “proposed” “continue” “estimates” “anticipates” “expects” “plans” “intends” “may” “could” “might” “will” “should” or other words that convey uncertainty of future events or outcomes to identify these forwardlooking statements such statements are subject to numerous important factors risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations for example there can be no guarantee that the company will obtain approval for zyn or zyn from the us food and drug administration fda or foreign regulatory authorities even if zyn or zyn are approved the company may not be able to obtain the label claims that it is seeking from the fda in addition the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated management’s expectations and therefore any forwardlooking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors including the following the success cost and timing of the company’s product development activities studies and clinical trials the success of competing products that are or become available the company’s ability to commercialize its product candidates the size and growth potential of the markets for the company’s product candidates and the company’s ability to service those markets the company’s ability to develop sales and marketing capabilities whether alone or with potential future collaborators the rate and degree of market acceptance of the company’s product candidates and the company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates this list is not exhaustive and these and other risks are described in the company’s periodic reports including the annual report on form k quarterly reports on form q and current reports on form k filed with or furnished to the securities and exchange commission and available at wwwsecgov any forwardlooking statements that the company makes in this press release speak only as of the date of this press release the company assumes no obligation to update forwardlooking statements whether as a result of new information future events or otherwise after the date of this press releasezynerba contacts jim fickenscher cfo and vp corporate development  fickenscherjzynerbacom will roberts vp investor relations and corporate communications  robertswzynerbacom related articles other press releases by zynerba pharmaceuticals inc zynerba pharmaceuticals mourns passing of director cynthia a rask july    zynerba pharmaceuticals added to the russell ® index june    zynerba pharmaceuticals initiates zyn phase  clinical program june    zynerba pharmaceuticals to present at the jefferies  global healthcare conference june    zynerba pharmaceuticals reports first quarter  financial results and operational highlights may     other news releases in product  services announcement in the last  days profile zynerba pharmaceuticals inc   subscribe via rss  subscribe via atom  javascript devon pennsylvania united states contact data zynerba contacts jim fickenscher cfo and vp corporate development  fickenscherjzynerbacom will roberts vp investor relations and corporate communications  robertswzynerbacom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files zynerba pharmaceuticals inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved zyne stock price  zynerba pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers algn  mhk  col  lyb  fls  mo  sbux  gt  latest newsall times eastern a breaking elon musk details tesla model  pricing range a tesla standard model  will cost  longrange model will cost   updated wall street isn’t ready for a point tumble in the dow industrials  barrons buzz robo  facebook and twitter trading on news  a wild week in washington  updated the dark side of cruises  trump to police dont be too nice  updated the highest paid athletes in the world in one chart  updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family  updated here are  coworkers you should avoid like the plague — especially in meetings to be replaced home investing quotes stocks united states zyne overview compare quotes stock screener earnings calendar sectors nasdaq zyne us nasdaq join td ameritrade find a broker zynerba pharmaceuticals inc watchlist createzynealert after hours last updated jul    pm edt delayed quote     after hours volume  close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones opinion how investors can separate the winners from the losers in the marijuana industry apr   at  am et by michael kahn opinion harry boxer these four momentum stocks are breaking out feb   at  pm et by harry boxer clinical development news jan  jan   at  pm et on the wall street journal it’s time for investors to relearn the lost art of reading apr   at  pm et on the wall street journal recent news other news press releases zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month jul   at  pm et on seeking alpha is the fda biotechs best friend is the fda biotechs best friend jul   at  am et on seeking alpha these  marijuana stocks all jumped at least  last week jul   at  am et on motley fool top marijuana stocks on the nasdaq most marijuana companies trade otc but these names are listed on the nasdaq and enjoy greater liquidity jul   at  am et on investopediacom forget gw pharmaceuticals these  stocks are better buys jul   at  am et on motley fool  things you need to know about marijuana stock zynerba pharmaceuticals jul   at  am et on motley fool gw pullback is a buy gw pullback is a buy jul   at  am et on seeking alpha brunch craft beer and investing a millennials portfolio brunch craft beer and investing a millennials portfolio jul   at  pm et on seeking alpha wow  of patients prefer medical marijuana to opioids new survey shows jul   at  am et on motley fool the  best stocks for  contest hits ’s midpoint the  best stocks for  contest hits ’s midpoint jul   at  pm et on investorplacecom zynerba shows promise in burgeoning cannabinoid market zynerba shows promise in burgeoning cannabinoid market jul   at  pm et on seeking alpha political risk increases for medical marijuana political risk increases for medical marijuana jul   at  am et on seeking alpha  marijuana stocks looking to combat the opioid epidemic jul   at  am et on motley fool zynerba pharmaceuticals zyne investor presentation  slideshow zynerba pharmaceuticals zyne investor presentation  slideshow jun   at  am et on seeking alpha zynerba pharmaceuticals scalable with less risk  debra borchardts idea of the month zynerba pharmaceuticals scalable with less risk  debra borchardts idea of the month jun   at  am et on seeking alpha  marijuana stocks it is still too early to buy the sector  marijuana stocks it is still too early to buy the sector jun   at  am et on seeking alpha medical marijuana investing recommendations medical marijuana investing recommendations jun   at  pm et on seeking alpha maxim bullish on zynerba pharmaceuticals inc zyne following meeting with management many investors hope to win big on biotech stocks as shares can sky rocket when  jun   at  pm et on smarteranalyst biotech forum daily digest  spotlight on  oncology concern verastem biotech forum daily digest  spotlight on  oncology concern verastem jun   at  am et on seeking alpha marijuana stock investors in awe as california goes toetotoe with the trump administration jun   at  am et on motley fool zynerba pharmaceuticals mourns passing of director cynthia a rask zynerba pharmaceuticals mourns passing of director cynthia a rask jul   at  am et on globenewswire biotech players lead the growth charge in the legal cannabis market biotech players lead the growth charge in the legal cannabis market jul   at  am et on pr newswire  prf potential blockbuster treatment for alzheimers disease stands out among medical cannabis companies potential blockbuster treatment for alzheimers disease stands out among medical cannabis companies jul   at  am et on pr newswire  prf billionaires bet big on canadas newest  billion market billionaires bet big on canadas newest  billion market jul   at  pm et on pr newswire  prf sales of legal cannabis products are expected to accelerate sales of legal cannabis products are expected to accelerate jul   at  am et on pr newswire  prf todays research reports on trending tickers insys therapeutics and zynerba pharmaceuticals todays research reports on trending tickers insys therapeutics and zynerba pharmaceuticals jul   at  am et on accesswire legal cannabis and cbdbased products projected to gain popularity legal cannabis and cbdbased products projected to gain popularity jun   at  am et on pr newswire  prf zynerba pharmaceuticals added to the russell r index zynerba pharmaceuticals added to the russell r index jun   at  am et on globenewswire zynerba pharmaceuticals initiates zyn phase  clinical program zynerba pharmaceuticals initiates zyn phase  clinical program jun   at  am et on globenewswire consumers spending on legal cannabis products projected to grow consumers spending on legal cannabis products projected to grow jun   at  am et on pr newswire  prf zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome jun   at  am et on globenewswire legal cannabis and cbd markets are projected to grow legal cannabis and cbd markets are projected to grow jun   at  am et on pr newswire  prf zynerba pharmaceuticals to present at the jefferies  global healthcare conference zynerba pharmaceuticals to present at the jefferies  global healthcare conference jun   at  am et on globenewswire how these generic drugs stocks are faring  myos rens technology akari therapeutics flexion therapeutics and zynerba pharma how these generic drugs stocks are faring  myos rens technology akari therapeutics flexion therapeutics and zynerba pharma may   at  am et on pr newswire  prf cannabisbased therapies with potential to dull the pain of opioid abuse cannabisbased therapies with potential to dull the pain of opioid abuse may   at  am et on pr newswire  prf legal cannabis and cbd markets grow in the united states legal cannabis and cbd markets grow in the united states may   at  am et on pr newswire  prf zynerba pharmaceuticals reports first quarter  financial results and operational highlights zynerba pharmaceuticals reports first quarter  financial results and operational highlights may   at  am et on globenewswire the creation of jobs in the legal cannabis market the creation of jobs in the legal cannabis market may   at  am et on pr newswire  prf the legal cannabis market expected to witness wider adoption apr   at  am et on pr newswire  prf how these generic drugs stocks are faring  zynerba pharma patheon scynexis and flexion therapeutics apr   at  am et on pr newswire  prf zynerba pharmaceuticals inc zynerba pharmaceuticals inc engages in the research and development of drugs its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery the company was founded by audra l stinchcomb on january   and is headquartered in devon pa see full profile analyst ratings sell under hold over buy number of ratings  full ratings viridian discusses the spicer effect on marijuana stocks it wasnt the deathblow some people were afraid of jun   at  am et on benzingacom catalysts growing like weeds for zynerba next quarter may   at  pm et on benzingacom  biggest price target changes for tuesday mar   at  am et on benzingacom competitors name chg  market cap omeros corp  m ohr pharmaceutical inc  m oncomed pharmaceuticals inc  m omni bio pharmaceutical inc  m competitor data provided by partner content trending tickers powered by dvax  sq  wfc  ben  wy  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft zynerba pharmaceuticals inc  nasdaqzyne  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street zynerba pharmaceuticals inc zyne follow  nasdaq  health care jul    pm edt prev close  day lowhigh     wk lowhigh    avg volume k exchange nasdaq shares outstanding m market cap m eps  pe ratio na div  yield na na trade with jim cramer  days free latest news zynerba pharmaceuticals mourns passing of director cynthia a rask notable thursday option activity zyne sf uthr zynerba pharmaceuticals added to the russell ® index jun    am edt zynerba pharmaceuticals initiates zyn phase  clinical program jun    am edt zynerba pharmaceuticals achieves target enrollment in exploratory phase  trial of zyn in fragile x syndrome  topline data from this study remains on track to report in september   jun    am edt launch of cannabis etf may not be best option for investors although a cannabis etf launched in april investors are still likely to find more value in buying individual stocks in the sector according to traders jun    pm edt zynerba pharmaceuticals to present at the jefferies  global healthcare conference jun    am edt zynerba pharmaceuticals reports first quarter  financial results and operational highlights may    am edt collect smokin hot profits from this marijuana biotech this innovative biotech offers investors an intriguing play on the medical marijuana business mar    pm edt zynerba pharmaceuticals reports fourth quarter and year end  financial results and operational highlights conference call to be held today at  am et mar    am edt cannabis coats and social media the good bad and ugly of s ipos in the first quarter of the year weve seen some highprofile ipos but theyre not all created equal heres what investors should keep an eye out for  and avoid mar    pm edt zynerba pharmaceuticals to report fourth quarter and fullyear  financial and operating results on march   conference call and webcast scheduled for  am et mar    am edt zynerba pharmaceuticals announces completion of enrollment for zyn in two phase  clinical trials for epilepsy and osteoarthritis topline data for both phase  clinical trials remains on track to report in julyaugust  mar    am edt zynerba pharmaceuticals to participate in upcoming investor conferences mar    am est zynerba pharmaceuticals announces full exercise of underwriters option to purchase additional shares feb    am est cannabis stocks do not trade on earnings instead on pipeline of drugs cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential fda approval on their pipeline of drugs jan    pm est zynerba pharmaceuticals announces pricing of public offering of common stock jan    am est gnc plummets mallinckrodt regains ground ahead of markets open heres how biotech and healthcare stocks are moving ahead of markets open jan    am est tech energy and financial stocks are set to reap highest returns for investors in  investors seeking less volatility can reap better returns in  by allocating funds in sectors such as technology biotech energy and financials which should generate above average performance jan    pm est zynerba pharmaceuticals announces proposed public offering of common stock jan    pm est fund manager high on marijuana zinc as shelters in pullback growth is almost guaranteed in these two areas says james mcdonald of index strategy advisors jan    am est  stocks making big moves with unusual volume heres a technical look at how to trade stocks rising with unusual volume flow jan    am est zynerba try some of this marijuana stock this smallcap has  intriguing medicinal compounds under development jan    am est zynerba pharmaceuticals announces initiation of the fabc exploratory phase  clinical trial of zyn cbd gel in patients with fragile x syndrome jan    am est zynerba pharmaceuticals to host clinical research day on december   to discuss the role of zyn cbd gel in multiple diseases dec    am est canadian marijuana market more mature outperforms us market the canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders dec    pm est zynerba reports positive results for zyn cbd gel in phase  studies at th annual meeting of the american epilepsy society dec    am est zynerba pharmaceuticals to highlight data for zyn cbd gel at the th annual meeting of the american epilepsy society nov    am est zynerba pharmaceuticals to participate in upcoming investor conferences nov    am est zynerba pharmaceuticals reports third quarter  financial results and operational highlights nov    am est next load more from our partners zynerba pharmaceuticals could run up due to upcoming key catalysts our idea of the month seekingalpha is the fda biotechs best friend seekingalpha gw pullback is a buy seekingalpha brunch craft beer and investing a millennials portfolio seekingalpha zynerba shares could rally to  on positive data says jefferies the fly zynerba shows promise in burgeoning cannabinoid market seekingalpha political risk increases for medical marijuana seekingalpha healthcare  top  gainers  losers as of  am seekingalpha zynerba pharmaceuticals zyne investor presentation  slideshow seekingalpha zynerba riskreward favorable after pullback says oppenheimer the fly zynerba pharmaceuticals scalable with less risk  debra borchardts idea of the month seekingalpha  marijuana stocks it is still too early to buy the sector seekingalpha medical marijuana investing recommendations seekingalpha healthcare  top  gainers  losers as of  am seekingalpha biotech forum daily digest  spotlight on  oncology concern verastem seekingalpha trending ftc seen as set to block rite aid deal it would be crazy to clean house at wells fargo ceo says tesla ceo elon musk we are going to be in production hell for  months advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers zynerba pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of zynerba pharmaceuticals inc snapshot people company overview zynerba pharmaceuticals inc a clinical stage specialty pharmaceutical company focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery its product candidates include zyn which is in phase ii clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis as well as pediatric patients with fragile x syndrome and zyn that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain the company was formerly known as alltranz inc and changed its name to zynerba pharmaceuticals inc in august  zynerba pharmaceuticals inc was founded in  and is zynerba pharmaceuticals inc a clinical stage specialty pharmaceutical company focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery its product candidates include zyn which is in phase ii clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis as well as pediatric patients with fragile x syndrome and zyn that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain the company was formerly known as alltranz inc and changed its name to zynerba pharmaceuticals inc in august  zynerba pharmaceuticals inc was founded in  and is headquartered in devon pennsylvania detailed description  west lancaster avenuesuite devon pa united statesfounded in  employees phone  wwwzynerbacom key executives for zynerba pharmaceuticals inc mr armando anido mba chairman and chief executive officer age  total annual compensation k ms terri b sebree president age  total annual compensation k mr james e fickenscher chief financial officer and vice president of corporate development age  total annual compensation k ms suzanne m hanlon vice president of human resources general counsel and secretary age  total annual compensation k compensation as of fiscal year  zynerba pharmaceuticals inc key developments zynerba pharmaceuticals inc initiates its zyn phase  clinical program jun   on june   zynerba pharmaceuticals inc announced that it has initiated its zyn phase  clinical program to study the companys patentprotected prodrug of tetrahydrocannabinol thc delivered via a transdermal patch this study will assess single and multiple rising doses of several formulations of zyn to identify the optimal dose to take into phase  studies the initiation of the zyn clinical program is an important milestone for the company as the company now have two clinical stage assets which upon approval may address serious unmet medical needs in a variety of disease settings said armando anido chairman and chief executive officer of zynerba the company believe that zyn will be important in a number of pain indications given thcs known impact on pain transmission and analgesic effect in patients suffering from chronic pain transdermal patch delivery offers unique advantages to patients including the potential for more consistent sustained delivery and better tolerability of thc this first in man study is a randomized doubleblind placebocontrolled phase  trial first the safety tolerability and pharmacokinetic profile of a single dose of zyn versus placebo will be evaluated several formulations and patch wear times ranging from  hours to  days will be assessed in up to  healthy subjects based on results from the single dose portion of this trial two formulations will be evaluated in multiple patch applications for  days in up to  healthy subjects who will be randomized  to zyn or placebo the goal is to deliver constant levels of thc to optimize efficacy while minimizing cns side effects with the successful completion of this single and multiple dose study a phase  program for zyn in fibromyalgia and neuropathic pain is planned to start in the second half of  zynerba pharmaceuticals inc announces enrollment target of  patients in phase  fabc treatment of fragile x syndrome anxiety and behavioral challenges with cbd clinical trial evaluating zyn cannabidiol cbd gel in children with fragile x syndrome jun   zynerba pharmaceuticals inc announced that it has met its enrollment target of  patients in its phase  fabc treatment of fragile x syndrome anxiety and behavioral challenges with cbd clinical trial evaluating zyn cannabidiol cbd gel in children with fragile x syndrome fxs zyn cbd gel is the first and only patentprotected synthetic cbd that is formulated as a permeationenhanced gel for transdermal delivery and was awarded orphan drug designation by the us food and drug administration for the treatment for fxs patients between the ages of  and  years with fragile x syndrome have been enrolled in the exploratory fabc trial which is designed to evaluate the safety and efficacy of zyn cbd gel administered over a week period in fxs the study is evaluating  mg of cbd in zyn  gel once daily which may be titrated up to  mg two times per day during the sixweek titration period between weeks six and twelve patients will receive a maintenance dose of  mg  mg or  mg daily of cbd in zyn  gel the primary outcome measures include changes in anxiety depression and mood as measured by the adams scale a patient reported outcomes questionnaire that has been validated in fxs other measurements that are being observed include the aberrant behavior checklist and visual analog scale vas to assess for hyperactivityimpulsivity fragile x syndrome is an autism spectrum disorder and the most common inherited intellectual disability in males and a significant cause of intellectual disability in females it is caused by a mutation in the fragile x mental retardation gene located on the x chromosome and leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids ag and anandamide the disorder negatively affects synaptic function plasticity and neuronal connections and results in a spectrum of intellectual disabilities social anxiety and memory problems in the us there are about  patients suffering with fxs zynerba pharmaceuticals inc presents at jefferies  global healthcare conference jun  pm jun   zynerba pharmaceuticals inc presents at jefferies  global healthcare conference jun  pm venue grand hyatt  e nd st new york new york united states speakers james e fickenscher chief financial officer and vice president of corporate development similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact zynerba pharmaceuticals inc please visit wwwzynerbacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close why zynerba pharmaceuticals inc is tanking today  the motley fool skip to main content the motley fool foolcom foolcouk foolcomau foolca foolsg foolde helping the world invest better since  hi fool premium advice help fool answers contact us login search search why zynerba pharmaceuticals inc is tanking today shares dropped after disappointing pricing details were released from the companys secondary common stock offering brian feroldi tmftypeoh jan   at am image source getty images what happened after zynerba pharmaceuticals nasdaqzynereleased the pricing information of its recently announced secondary common stock offering its shares fell by more than  as of  am est on thursday so what zynerba pharmaceuticals announced that it is selling  million shares of its common stock at a price of  per share the offering is expected to net the company slightly more than  million in addition the underwriters of the deal are also being granted a day option to purchase up to  additional shares of common stock which could potentially pad its bank account by another  million traders are not reacting kindly to this news because zynerbas stock ended wednesdays trading session at  thus the pricing terms of the deal suggest that the company was forced to offer a  discount in order to attract enough demand from investors thats not exactly an encouraging sign zynerba said that the proceeds of the deal will be used to fund the clinical development its two transdermal synthetic cannabinoid product candidates  which are called zyn and zyn  as well as for general corporate purposes the markets responded to the disappointing pricing terms by knocking down the companys share price by double digits now what after this transaction is complete zynerbas cash balance should exceed  million if its current spending levels hold then it should easily have enough capital to fund itself for at least two more years that should be enough time for the company to make a lot of progress on its clinical development heres a look at zynerbas pipeline as it stands today image source zynerba pharmaceuticals zyn remains the most interesting drug for investors to watch since it is nearing the end of two phase  clinical trials this product candidate is a cannabinoidbased get that delivers its payload through the skin the company believes that it could be used to treat a variety of diseases such as refractory epilepsy osteoarthritis of the knee and fragile x syndrome with topline results for its star  and stop trials expected to be released in the next few months investors wont have to wait long to see how this interesting product candidate performs in the clinic however until those results are released id suggest that potential shareholder should keep zynerba as a watchlistonly stock for now  brian feroldi has no position in any stocks mentioned like this article follow him on twitter where he goes by the handle brianferoldi or connect with him on linkedin to see more articles like this the motley fool has no position in any of the stocks mentioned the motley fool has a disclosure policy author brian feroldi tmftypeoh foolish investor brian feroldi has been covering the healthcare industry for the motley fool since  brians investing goal is to buy the highest quality companies that he can find and then let compounding work its magic see all of his articles here and make sure you follow him on twitter follow brianferoldi article info jan   at am health care stocks zynerba pharmaceuticals nasdaqzyne  down   read more these  marijuana stocks all jumped at least  last week prev     next compare brokers motley fool push notifications are finally here allow push notifications to help you stay on top of breaking investing news earnings coverage market movers special offers and more subscribe to notifications you can unsubscribe at any time current why zynerba pharmaceuticals inc is tanking today themotleyfool stocks zyne zynerba pharmaceuticals inc  zyne  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  generic drugs zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for zyne all zacks’ analyst reports premium research for zyne zacks rank hold  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores f value  f growth  b momentum  f vgm earnings esp  research report for zyne snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank zynerba pharmaceuticals inc zyne aspen pharmacr apnhy acura pharmaceuticals inc acur adamas pharmaceuticals inc adms akorn inc akrx allergan plc agn amphastar pharmaceuticals inc amph see all medical  generic drugs peers zacks news for zyne implied volatility surging for zynerba pharmaceuticals zyne stock options am est zacks play the marijuana rush as first marijuanafocused etf launches am est zacks zyne what are zacks experts saying now zacks private portfolio services agile therapeutics agrx catches eye stock moves up  am est zacks cooper coo to report q earnings is a surprise in store am est zacks dexcom dxcm q earnings what to expect from the stock am est zacks company summary zynerba pharmaceuticals inc is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery its product candidates which are in clinical trial stage include zyn and zyn synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy fragile x syndrome osteoarthritis fibromyalgia and peripheral neuropathic pain zynerba pharmaceuticals inc is headquartered in devon pennsylvania